Matches in Nanopublications for { ?s <http://www.w3.org/2000/01/rdf-schema#label> ?o ?g. }
- association label "Among the four disease states (anxiety, demen- tia, insomnia, and PTSD), a total of 29 scenarios were investigated for each drug. None of the sce- narios were judged by the expert panel to be appropriate for use of an antipsychotic." assertion.
- cohort label "Elderly" assertion.
- association label "Among the four disease states (anxiety, demen- tia, insomnia, and PTSD), a total of 29 scenarios were investigated for each drug. None of the sce- narios were judged by the expert panel to be appropriate for use of an antipsychotic." assertion.
- cohort label "Elderly" assertion.
- association label "Among the four disease states (anxiety, demen- tia, insomnia, and PTSD), a total of 29 scenarios were investigated for each drug. None of the sce- narios were judged by the expert panel to be appropriate for use of an antipsychotic." assertion.
- association label "Among the four disease states (anxiety, demen- tia, insomnia, and PTSD), a total of 29 scenarios were investigated for each drug. None of the sce- narios were judged by the expert panel to be appropriate for use of an antipsychotic." assertion.
- cohort label "Elderly" assertion.
- MONDO_0001627 label "dementia (disease)" assertion.
- spi label "the protein TDP-43 represses cryptic exon inclusion in the gene UNC13A" assertion.
- association label "Among the four disease states (anxiety, demen- tia, insomnia, and PTSD), a total of 29 scenarios were investigated for each drug. None of the sce- narios were judged by the expert panel to be appropriate for use of an antipsychotic." assertion.
- cohort label "Elderly" assertion.
- association label "Among the four disease states (anxiety, demen- tia, insomnia, and PTSD), a total of 29 scenarios were investigated for each drug. None of the sce- narios were judged by the expert panel to be appropriate for use of an antipsychotic." assertion.
- cohort label "Elderly" assertion.
- association label "Among the four disease states (anxiety, demen- tia, insomnia, and PTSD), a total of 29 scenarios were investigated for each drug. None of the sce- narios were judged by the expert panel to be appropriate for use of an antipsychotic." assertion.
- cohort label "Elderly" assertion.
- cohort label "Elderly" assertion.
- association label "Among the four disease states (anxiety, demen- tia, insomnia, and PTSD), a total of 29 scenarios were investigated for each drug. None of the sce- narios were judged by the expert panel to be appropriate for use of an antipsychotic." assertion.
- cohort label "Elderly" assertion.
- association label "Among the four disease states (anxiety, demen- tia, insomnia, and PTSD), a total of 29 scenarios were investigated for each drug. None of the sce- narios were judged by the expert panel to be appropriate for use of an antipsychotic." assertion.
- association label "Among the four disease states (anxiety, demen- tia, insomnia, and PTSD), a total of 29 scenarios were investigated for each drug. None of the sce- narios were judged by the expert panel to be appropriate for use of an antipsychotic." assertion.
- cohort label "Elderly" assertion.
- cohort label "Elderly" assertion.
- association label "Among the four disease states (anxiety, demen- tia, insomnia, and PTSD), a total of 29 scenarios were investigated for each drug. None of the sce- narios were judged by the expert panel to be appropriate for use of an antipsychotic." assertion.
- association label "Antipsychotics have been found to reduce BPD symptoms including aripiprazole (mean daily dose: 15 mg); ziprasidone (mean daily dose: 20 to 80 mg), olanzapine (mean daily dose: 5 to 9 mg, daily dose range 5 to 20 mg), haloperidol (mean daily dose 5 mg, daily dose range 4 to 16 mg), Quetiapine XL (at a daily dose of 150 mg)." assertion.
- cohort label "Adults" assertion.
- MONDO_0001156 label "Borderline personality disorder (disease)" assertion.
- MONDO_0001156 label "Borderline personality disorder (disease)" assertion.
- MONDO_0001156 label "Borderline personality disorder (disease)" assertion.
- MONDO_0001156 label "Borderline personality disorder (disease)" assertion.
- MONDO_0001156 label "Borderline personality disorder (disease)" assertion.
- MONDO_0001156 label "Borderline personality disorder (disease)" assertion.
- MONDO_0001156 label "Borderline personality disorder (disease)" assertion.
- MONDO_0001156 label "Borderline personality disorder (disease)" assertion.
- MONDO_0001156 label "Borderline personality disorder" assertion.
- MONDO_0001156 label "borderline personality disorder (disease)" assertion.
- cohort label "Adults" assertion.
- association label "Antipsychotics have been found to reduce BPD symptoms including aripiprazole (mean daily dose: 15 mg); ziprasidone (mean daily dose: 20 to 80 mg), olanzapine (mean daily dose: 5 to 9 mg, daily dose range 5 to 20 mg), haloperidol (mean daily dose 5 mg, daily dose range 4 to 16 mg), Quetiapine XL (at a daily dose of 150 mg). The empirically use of antipsychotics in patients with BPD are considered as off-label use." assertion.
- association label "Of relevance, lisdexamfetamine dimesylate, a psy- chostimulant approved for the treatment of ADHD, has been recently assessed and approved for the treat- ment of moderate to severe binge eating disorder in adults.5,6 In a phase 2 efficacy and safety trial, pa- tients with binge eating disorder who were prescribed doses of 50 and 70 mg/day doses of lisdexamfetamine demonstrated reduced binge eating days per week, greater binge eating cessation rates, and greater rates of clinical global improvement at 11 weeks compared with the placebo control group" assertion.
- cohort label "Adults" assertion.
- MONDO_0005452 label "bulimia" assertion.
- MONDO_0005452 label "bulimia nervosa" assertion.
- MONDO_0005452 label "bulimia nervosa" assertion.
- MONDO_0005452 label "bulimia nervosa" assertion.
- MONDO_0005452 label "Bulimia Nervosa" assertion.
- association label "Quetiapine, an atypical antipsychotic drug, is recommended for the treatment of schizophrenia and mood disorders. In addition, given its sedative effects, a low dose of the agent is also widely used in the treatment of anxiety disorders, personality disorders, substance abuse, and sleep disturbances." assertion.
- cohort label "Adults" assertion.
- LinguisticSystem label "python" assertion.
- out1 label "out1" assertion.
- image label "image" assertion.
- step label "Awesome step for rotating an image" assertion.
- out1 label "out1" assertion.
- image label "image" assertion.
- LinguisticSystem label "python" assertion.
- angle_rotation label "angle_rotation" assertion.
- step label "Awesome step for rotating an image" assertion.
- cohort label "Adults" assertion.
- association label "This practice is also observed with increased off-label use of psychotropic drugs includ- ing selective serotonin reuptake inhibitors (SSRIs) [12] for repetitive behaviors, stimulant medications for attention- deficit hyperactivity disorder (ADHD)-type symptoms [25], and anti-epileptic medications such as valproate for behavioral symptoms in ASD [26]." assertion.
- cohort label "Adults" assertion.
- association label "Quetiapine is prescribed off-label for many disorders including the following: • Augmentation in major depressive disorder; • Obsessive–compulsive disorder; • Post-traumatic stress disorder; • Insomnia; • Behavioural disturbance in dementia; • Borderline personality disorder; • Alcohol dependence; • Cannabis withdrawal." assertion.
- association label "Quetiapine is prescribed off-label for many disorders including the following: • Augmentation in major depressive disorder; • Obsessive–compulsive disorder; • Post-traumatic stress disorder; • Insomnia; • Behavioural disturbance in dementia; • Borderline personality disorder; • Alcohol dependence; • Cannabis withdrawal." assertion.
- cohort label "Adults" assertion.
- step label "awesome step to pixelize an image, with adjustable rate" assertion.
- out1 label "out1" assertion.
- img label "img" assertion.
- rate label "rate" assertion.
- LinguisticSystem label "python" assertion.
- out1 label "out1" assertion.
- LinguisticSystem label "python" assertion.
- step label "awesome image converter" assertion.
- image label "image" assertion.
- LinguisticSystem label "python" assertion.
- step label "awesome image converter" assertion.
- out1 label "out1" assertion.
- image label "image" assertion.
- step label "awesome image converter" assertion.
- image label "image" assertion.
- out1 label "out1" assertion.
- LinguisticSystem label "python" assertion.
- step label "Put here a name of your awesome step (include the word awesome so others will find it)" assertion.
- image label "image" assertion.
- LinguisticSystem label "python" assertion.
- out1 label "out1" assertion.
- out1 label "out1" assertion.
- LinguisticSystem label "python" assertion.
- image label "image" assertion.
- step label "Put here a name of your awesome step (include the word awesome so others will find it)" assertion.
- out1 label "out1" assertion.
- img label "img" assertion.
- LinguisticSystem label "python" assertion.
- step label "Convert the image" assertion.
- spi label "NGLY1 deficiency is a novel autosomal recessive disorder of the ERAD pathway." assertion.
- possiblevaluesfromapi label "URL prefix for API lookup" assertion.
- possiblevaluesfrom label "nanopublication with possible values" assertion.
- placeholderWithRegex label "short ID of placeholder" assertion.
- tstatementx label "short ID of simple statement" assertion.
- statementWithStatementOrder label "short ID of statement" assertion.
- tsubj label "URI/placeholder of the subject" assertion.
- tstatementi label "short ID of statement" assertion.
- placeholderWithPrefix label "short ID of placeholder" assertion.
- reqpubinfo label "Nanopublication URI with publication info template" assertion.